1. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Updated 2019. https://www.nice.org.uk/guidance/NG122.
2. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NICE guideline 12). Updated 2017. https://www.nice.org.uk/guidance/NG12.
3. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Systemic anticancer therapy management options for people with squamous non-small cell carcinoma. 2019. www.nice.org.uk/guidance/ng122/resources/systemic-anticancer-therapy-management-options-for-people-with-squamous-nonsmallcell-carcinoma-pdf-6722110910.
4. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline 122). Systemic anticancer therapy management options for people with non-squamous adenocarcinoma, large cell undifferentiated carcinoma, and non-small cell carcinoma not otherwise specified. 2019. www.nice.org.uk/guidance/ng122/resources/systemic-anticancer-therapy-management-options-for-people-with-nonsquamous-adenocarcinomalarge-cell-undifferentiated-carcinoma-and-nonsmallcell-carcinoma-nonotherwise-specified-pdf-6722110909.